Five Prime Therapeutics Receives Early HSR Clearance for FPA008 License, Collaboration Agreement With Bristol-Myers Squibb

By: via Benzinga
Five Prime Therapeutics, Inc. (Nasdaq: FPRX) announced that the Federal Trade Commission has granted early termination of the waiting ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.